{"id":"gleevec-and-arsenic-trioxide","safety":{"commonSideEffects":[{"rate":"50-60%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gleevec is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR proteins. Arsenic trioxide is a differentiating agent that induces apoptosis in leukemia cells.","oneSentence":"Tyrosine kinase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:38:35.443Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia"},{"name":"Acute promyelocytic leukemia"}]},"trialDetails":[{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT01397734","phase":"PHASE1","title":"Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2011-09","conditions":"Chronic Myelogenous Leukemia","enrollment":7},{"nctId":"NCT00081133","phase":"PHASE1, PHASE2","title":"Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-12","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00053248","phase":"PHASE1, PHASE2","title":"Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2002-10","conditions":"Leukemia","enrollment":16},{"nctId":"NCT00250042","phase":"PHASE2","title":"A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec","status":"COMPLETED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2004-04","conditions":"Leukemia, Other, Cancer","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Gleevec and Arsenic Trioxide","genericName":"Gleevec and Arsenic Trioxide","companyName":"New Mexico Cancer Research Alliance","companyId":"new-mexico-cancer-research-alliance","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gleevec (imatinib mesylate) is a small molecule used to treat Chronic Myelogenous Leukemia and other conditions, including Urothelial Carcinoma. Arsenic Trioxide is also a small molecule used to treat Chronic Myelogenous Leukemia, among other conditions, and has been studied in combination with Gleevec in clinical trials.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}